New SwiftArrayStudio analyzer and updated genotyping arrays deliver results in as little as 30 hours, enabling researchers to drive impactful, scalable genetic researchWALTHAM, Mass.--(BUSINESS WIRE)- ...

About Vaxxas Vaxxas is a biotechnology company pioneering a needle-free vaccination technology designed to enhance immune response, reduce costs, and improve accessibility. The company recently ...

Thermo Fisher Scientific (TMO) just posted third-quarter results that came in ahead of expectations, showing healthy revenue ...

Genomics company Illumina (NASDAQ:ILMN) in Q3 CY2025, but sales were flat year on year at $1.08 billion. Its non-GAAP profit of $1.34 per share was 14.7% above analysts’ consensus estimates. Is now ...

This report provides a comprehensive analysis of the next-generation proteomics market, highlighting key trends, drivers and ...

Before receiving the implant, it was like having two black discs in my eyes, with the outside distorted,” said Sheila Irvine, ...

The treatment involves inserting a tiny implant thinner than human hair under the retina. Patients then have to wear glasses ...

An electronic eye implant has restored vision in people with blindness caused by age-related macular degeneration.

Australian biotech Vaxxas has signed a three-year agreement with US-based digital clinical trial specialist ObvioHealth to advance commercialisation of the Bris ...

Geographic atrophy, an advanced form of dry age-related macular degeneration, leaves almost five million people around the ...

Of the 38 patients with age-related macular degeneration, 80% were able to read again after having the eye implant and using ...